Roles of the Artemis nuclease in DNA repair and disease
Artemis 核酸酶在 DNA 修复和疾病中的作用
基本信息
- 批准号:7162080
- 负责人:
- 金额:$ 28.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-01-01 至 2009-12-31
- 项目状态:已结题
- 来源:
- 关键词:Active SitesAntigen ReceptorsAntigensBindingBiochemicalBiologicalBiological ProcessCatalysisCatalytic DomainCellular AssayChromosome abnormalityDNADNA DamageDNA Double Strand BreakDNA RepairDNA StructureDNA-dependent protein kinaseDefectDevelopmentDiseaseDisease OutcomeDouble Strand Break RepairEnzymesExhibitsExonucleaseFundingGene TargetingGenesGeneticGoalsHumanHypersensitivityImmune responseImmune systemImmunologic Deficiency SyndromesIndividualJ segment geneLactamaseLeadLymphocyteLymphoidLymphomaMalignant lymphoid neoplasmMolecularMusMutateMutationNonhomologous DNA End JoiningPatientsPhenotypePhosphorylationPredispositionPrincipal InvestigatorProcessProtein FamilyProtein-Serine-Threonine KinasesProteinsRAG1 geneRadiation ToleranceRegulationResearch PersonnelRoleSequence HomologySevere Combined ImmunodeficiencySite-Directed MutagenesisStagingSurfaceT-LymphocyteTranslationsV(D)J Recombinationartemisbaseendonucleasehuman diseasein vivoinsightmembermutantnucleaseprogramsreceptorspleen exonucleasetumorigenesis
项目摘要
DESCRIPTION (provided by applicant): During the initial stages of the immune response against foreign antigens, a vast array of receptors expressed on the surface of B and T cells recognize and bind the myriad of foreign molecules. Diversity amongst the genes encoding the recognition regions of antigen receptors is generated through V(D)J recombination, a process in which individual V, D, and J gene segments are rearranged. Two types of activities are required for V(D)J recombination; lymphoid-specific factors, such as recombination activating genes 1 and 2 (RAG1/2), and the ubiquitously expressed non-homologous end-joining (NHEJ) DNA repair factors, such as Artemis. Mutations in Artemis are known to cause a human severe combined immunodeficiency syndrome associated with cellular radiosensitivity (RS-SCID). Recent evidence suggests that hypomorphic mutations in Artemis may also predispose to lymphoma in human patients. Artemis, a 76 kDa protein, possesses single strand 5' to 3' exonuclease activity and acquires endonucleolytic activity upon interaction with and phosphorylation by the DNA-dependent protein kinase catalytic subunit (DNA-PKcs). In addition to its role in V(D)J recombination, Artemis is also required for general DNA double strand break repair (DSB) and suppressing chromosomal aberrations, including translocations and telomeric fusions. It is not yet known whether both exo- and endonucleolytic activities or regulation by DNA-PKcs are required for each of the multiple functions of Artemis, nor is it clear what impact the Artemis mutations found in human patients have on its intrinsic biochemical activities. Thus, the goals of the specific aims described in this proposal are to use combined biochemical, cellular and genetic approaches to further elucidate the catalytic repertoire and in vivo roles of Artemis. These studies will provide a more clear understanding of the functions of Artemis in DNA repair processes and insights into the molecular mechanisms underlying immune system defects and predisposition to lymphoid malignancies in human patients.
描述(由申请人提供):在针对外来抗原的免疫反应的初始阶段,B和T细胞表面表达的大量受体识别并结合无数的外来分子。编码抗原受体识别区域的基因之间的多样性是通过 V(D)J 重组产生的,在该过程中各个 V、D 和 J 基因片段重新排列。 V(D)J 重组需要两种类型的活动:淋巴特异性因子,例如重组激活基因 1 和 2 (RAG1/2),以及普遍表达的非同源末端连接 (NHEJ) DNA 修复因子,例如 Artemis。众所周知,Artemis 的突变会导致人类严重的与细胞放射敏感性相关的联合免疫缺陷综合征 (RS-SCID)。最近的证据表明,Artemis 的亚等位基因突变也可能导致人类患者罹患淋巴瘤。 Artemis 是一种 76 kDa 的蛋白质,具有单链 5' 至 3' 核酸外切酶活性,并在与 DNA 依赖性蛋白激酶催化亚基 (DNA-PKcs) 相互作用并被其磷酸化后获得核酸内切活性。除了在 V(D)J 重组中发挥作用外,Artemis 还需要进行一般 DNA 双链断裂修复 (DSB) 和抑制染色体畸变,包括易位和端粒融合。目前尚不清楚 Artemis 的多种功能是否需要外切和内切核酸酶活性或 DNA-PKcs 的调节,也不清楚在人类患者中发现的 Artemis 突变对其内在生化活性有何影响。因此,本提案中描述的具体目标的目标是使用组合的生化、细胞和遗传学方法来进一步阐明 Artemis 的催化功能和体内作用。这些研究将使人们更清楚地了解 Artemis 在 DNA 修复过程中的功能,并深入了解人类患者免疫系统缺陷和淋巴恶性肿瘤易感性的分子机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JoAnn Sekiguchi其他文献
JoAnn Sekiguchi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JoAnn Sekiguchi', 18)}}的其他基金
Myeloablative conditioning and late complications in ARTEMIS-deficient SCID
ARTEMIS 缺陷 SCID 的清髓调理和晚期并发症
- 批准号:
9251366 - 财政年份:2017
- 资助金额:
$ 28.51万 - 项目类别:
Molecular mechanisms of lung disease in ataxia telangiectasia
共济失调性毛细血管扩张性肺部疾病的分子机制
- 批准号:
8204498 - 财政年份:2010
- 资助金额:
$ 28.51万 - 项目类别:
Roles of the Artemis nuclease in DNA repair and disease
Artemis 核酸酶在 DNA 修复和疾病中的作用
- 批准号:
8072925 - 财政年份:2010
- 资助金额:
$ 28.51万 - 项目类别:
Mechanism and regulation of DNA end processing in V(D)J recombination and repair
V(D)J重组和修复中DNA末端加工的机制和调控
- 批准号:
8116793 - 财政年份:2010
- 资助金额:
$ 28.51万 - 项目类别:
Molecular mechanisms of lung disease in ataxia telangiectasia
共济失调性毛细血管扩张性肺部疾病的分子机制
- 批准号:
8582506 - 财政年份:2010
- 资助金额:
$ 28.51万 - 项目类别:
Molecular mechanisms of lung disease in ataxia telangiectasia
共济失调性毛细血管扩张性肺部疾病的分子机制
- 批准号:
8386672 - 财政年份:2010
- 资助金额:
$ 28.51万 - 项目类别:
Molecular mechanisms of lung disease in ataxia telangiectasia
共济失调性毛细血管扩张性肺部疾病的分子机制
- 批准号:
8040274 - 财政年份:2010
- 资助金额:
$ 28.51万 - 项目类别:
Molecular mechanisms of lung disease in ataxia telangiectasia
共济失调性毛细血管扩张性肺部疾病的分子机制
- 批准号:
8204498 - 财政年份:2010
- 资助金额:
$ 28.51万 - 项目类别:
Roles of the Artemis nuclease in DNA repair and disease
Artemis 核酸酶在 DNA 修复和疾病中的作用
- 批准号:
6993660 - 财政年份:2005
- 资助金额:
$ 28.51万 - 项目类别:
Mechanism and regulation of DNA end processing in V(D)J recombination and repair
V(D)J重组和修复中DNA末端加工的机制和调控
- 批准号:
8488394 - 财政年份:2005
- 资助金额:
$ 28.51万 - 项目类别:
相似国自然基金
脂质纳米粒体内介导嵌合抗原受体-M1型巨噬细胞协同TLR激动剂治疗实体瘤的研究
- 批准号:82304418
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
嵌合抗原受体巨噬细胞(CAR-M)微马达的制备及其血管蜂窝网络磁驱行为机理与控制方法研究
- 批准号:52375565
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
双靶向CSPG4/CD126嵌合抗原受体修饰的复制缺失型弓形虫减毒活疫苗(CAR-Tg)抗恶性黑色素瘤的效应及机制研究
- 批准号:32370997
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
体内构建嵌合抗原受体Kupffer细胞(CAR-KC)并借助“细胞变装”策略实现肝癌双靶杀伤
- 批准号:82304398
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向B细胞治疗系统性红斑狼疮的体内嵌合抗原受体T细胞(CAR-T)基因纳米递送体系的研究
- 批准号:82302379
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Fusion: Vaccine conjugate technology to advance vaccine safety and efficacy
Fusion:疫苗结合技术可提高疫苗的安全性和有效性
- 批准号:
10402889 - 财政年份:2018
- 资助金额:
$ 28.51万 - 项目类别:
Fusion: Vaccine conjugate technology to advance vaccine safety and efficacy
Fusion:疫苗结合技术可提高疫苗的安全性和有效性
- 批准号:
10183150 - 财政年份:2018
- 资助金额:
$ 28.51万 - 项目类别:
Structure/function studies of immunogen recognition by anti-HIV antibody b12
抗HIV抗体b12免疫原识别的结构/功能研究
- 批准号:
8463117 - 财政年份:2013
- 资助金额:
$ 28.51万 - 项目类别:
Structure/function studies of immunogen recognition by anti-HIV antibody b12
抗HIV抗体b12免疫原识别的结构/功能研究
- 批准号:
8117982 - 财政年份:2011
- 资助金额:
$ 28.51万 - 项目类别:
Roles of the Artemis nuclease in DNA repair and disease
Artemis 核酸酶在 DNA 修复和疾病中的作用
- 批准号:
8072925 - 财政年份:2010
- 资助金额:
$ 28.51万 - 项目类别: